600211 西藏药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入723,5481.61%2,981,5382,806,7133,134,3282,554,609
减:营业总成本502,68518.39%1,988,7341,865,6912,058,2971,813,092
    其中:营业成本51,37637.57%172,475162,297155,085146,694
               财务费用(7,453)-80.70%(69,078)(47,181)(33,712)4,291
               资产减值损失(174)--(4,845)198(193,970)(276,664)
公允价值变动收益(2,142)50.43%1,662(18,985)(210,533)(14,167)
投资收益1,447-73.58%7,48115,10440,4427,023
    其中:对联营企业和合营企业的投资收益(3,785)411.24%(13,854)(5,489)(4,271)(2,223)
营业利润316,2974.56%1,043,8321,160,450899,093464,653
利润总额316,6374.97%1,040,6181,152,084898,195463,392
减:所得税费用33,8047.66%123,63795,00987,95088,083
净利润282,8334.66%916,9811,057,075810,245375,309
减:非控股权益(15,876)-1,739.47%(20,950)5,7879,3315,469
股东净利润298,70910.93%937,9311,051,288800,914369,840

市场价值指针
每股收益 (元) *0.93010.71%2.9103.2602.4801.490
每股派息 (元) *----1.7571.9571.9390.746
每股净资产 (元) *12.100-4.90%11.78512.15513.49012.147
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容